Therefore, significantly lower amounts of recombinant IL-2 may be used in the treatment of autoimmune diseases such as post-CHIKV chronic arthritis compared to dosages used in cancer therapy; however, further trials are needed to clarify the optimal low dose in CHIKV arthritis. Here, IL2 is linked to autoimmune disease.